PGNYProgyny, Inc.

Healthcare

$27.94+29% 1Y

$27.94

$16.3052 weeks$32.37

Is the price fair?

Good

Undemanding: modest expectations priced in and cheap against its own history.

2 good, 1 neutral

What the price assumes~−1% a yearderived · Jun 30, 2026

Priced for a decline (~−1% a year). The price demands less than its three-year revenue growth of 11% a year, expectations look modest.

Vs its own P/E rangecheaper than 79% of its own historyderived

Cheap vs its own history: P/E 30.4 vs a 62.2 median over 19 quarters (−51% vs median).

Vs sector (EV/EBIT)21.5×derived · Dec 31, 2025

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)behind 68% of the market

FCF yieldbetter than 78% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What PGNY's price assumes

Progyny, Inc. trades at 30.4× earnings against 25.0× for the median Healthcare Plans name, more expensive than its own group.

30.4

Trailing P/E · Healthcare Plans median 25.0 · 1.21× the median: the market pays up for this one

Price / sales: 1.66
Price / sales · today's price, fiscal year to Dec 31, 2025
Free cash flow yield: 8.3%
Free cash flow yield · Healthcare Plans median 6.5%
Growth the price implies: −1.1%
Growth the price implies · The price pays for −1.1% free cash flow growth a year for a decade; the business has delivered +2.5% a year over the last three.